BofA lowered the firm’s price target on RxSight (RXST) to $9 from $18 and keeps an Underperform rating on the shares. The results of the last two quarters raise concerns about near-term adoption and it is hard to be confident that the guide is derisked as RxSight does not appear to have great visibility, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight downgraded to Perform from Outperform at Oppenheimer
- RxSight price target lowered to $9 from $17 at Stifel
- RxSight downgraded to Neutral from Buy at BTIG
- RxSight’s Strategic Initiatives and International Expansion Support Buy Rating Amidst Revenue Challenges
- RxSight downgraded to Equal Weight from Overweight at Wells Fargo